In the field of cardio-oncology, it is well recognised that despite the benefits of chemotherapy
in treating and possibly curing cancer, it can cause catastrophic damage to bystander …

Background Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor
antagonist of vascular endothelial growth factor receptor 2, has been approved for treating …

Volume 38, Number 3, 2011 264 Hypertension in Cancer Patients treatment of high blood
pressure, 11 while oncologists are more familiar with the common terminology criteria for …

HTN-C can be a de-novo manifestation or a complication of essential or secondary HTN.
The presence of acute EOD is a major poor prognostic indicator in HTN-C. The main …

Background The receptor kinase inhibitor toceranib phosphate (Palladia) was approved for
use in dogs in 2009 using a dose of 3.25 mg/kg administered every other day. Preliminary …

Background This study was to investigate the efficacy and safety of anlotinib for elderly
patients with previously treated extensive-stage small cell lung cancer (ES-SCLC) and the …

Background Effective treatment options for inoperable, metastatic, or recurrent canine
pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the …

AKI in the setting of HSCT is commonly investigated among adult patients. In the same way,
malignancies requiring treatment with HSCT are not limited to the adult patient population …

Angiogenesis is critical to tumor growth as well as to metastases. This process is tightly
regulated by pro-and anti-angiogenic growth factors and their receptors. Some of these …

Cancer and cardiovascular disease are the most common causes of mortality in the US,
causing approximately 1.2 million deaths annually. The incidence of cancer is expected to …